Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats.
This study evaluated the activity of cardiac and renal antioxidant enzymes [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), and glutathione reductase (GR)] and whether chronic treatment with tempol, a cell membrane-permeable SOD mimetic, ameliorates the hypertension of hyperthyroidism. Two experiments were performed. In experiment I, the following four groups of male Wistar rats were used: control group and three groups that received thyroxine (T4) at 10, 50, or 75 microg x rat(-1) x day(-1). In experiment II, tempol was orally administered (18 mg x kg(-1) x day(-1)) to control and T4-treated (75 microg x rat(-1) x day(-1)) rats. All treatments were maintained for 6 wk. Body weight, tail systolic blood pressure (BP), and heart rate were measured one time a week, and direct BP and morphological, metabolic, plasma, and renal variables were measured at the end of the experiment. Enzymatic activities were measured in renal cortex and medulla and right and left ventricles. In renal cortex, SOD activity was decreased in the T4-75 group, and there was a dose-related increase in CAT activity and decrease in GPX and GR activities in T4-treated groups. Activity of all antioxidant enzymes was reduced in left ventricle in T4-50 and T4-75 groups and in right ventricle in the T4-75 group. Tempol reduced BP, plasma malondialdehyde, and total urinary excretion of F2 isoprostanes in hypertensive hyperthyroid rats but not in controls. Tempol did not improve cardiac hypertrophy, proteinuria, or creatinine clearance in hyperthyroid rats. In conclusion, the results obtained indicate that the activity of SOD, GPX, and GR in renal and cardiac tissues is decreased in hyperthyroidism and that antioxidant treatment with tempol ameliorates T4-induced hypertension.
Moreno
Juan Manuel
JM
Servicio de Nefrología, Unidad Experimental, Hospital Virgen de las Nieves, Granada, Spain.
Rodríguez Gómez
Isabel
I
Wangensteen
Rosemary
R
Osuna
Antonio
A
Bueno
Pablo
P
Vargas
Félix
F
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002374:Catalase / Q000378:metabolism; D003497:Cyclic N-Oxides / Q000494:pharmacology*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000652:urine; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology; D006980:Hyperthyroidism / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology*; D007668:Kidney / Q000201:enzymology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009206:Myocardium / Q000201:enzymology*; D051381:Rats; D017208:Rats, Wistar; D013113:Spin Labels; D013482:Superoxide Dismutase / Q000378:metabolism; D013974:Thyroxine / Q000494:pharmacology
D000975:Antioxidants; D003497:Cyclic N-Oxides; D013113:Spin Labels; C075750:8-epi-prostaglandin F2alpha; D008315:Malondialdehyde; D015237:Dinoprost; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D013974:Thyroxine; C001803:tempol